Medela, Inc., a global medical technology and breastfeeding organization, today launched its Invia® Healing System, a negative pressure wound therapy (NPWT) system used to safely and effectively heal chronic and acute wounds. The new system’s infection-preventing dual mechanism includes antimicrobial properties and active drainage that control infection.
Medela’s new Invia® Healing System includes the Medela-manufactured Vario 18 AC/DC c/i aspirator pump, which applies a gentle negative pressure to the wound, and an advanced wound dressing kit that controls infection and promotes healing. Most NPWT systems use foam to dress the wound, but Invia® includes a gauze-based dressing that is antimicrobial and designed to stop infection before it starts. The FDA-cleared system is also designed for easy application, to minimize nursing time and patient discomfort as well as to expedite the healing process. Invia® can be used to heal various types of wounds including diabetic/neuropathic and pressure wounds; chronic, acute and dehisced wounds; partial-thickness burns; and flaps and grafts.
“We’re committed to improving the health and life of patients by offering the market increased choice with competitively-priced, high-quality, research-based products,” explained Bernie Laurel, vice president, Medela Healthcare Americas.
The Invia® Healing System will be available to the acute care market first followed by extended care, long term care, and home care. Medela is expanding its own sales force and will simultaneously integrate strategic sales partners and specialized distributors to provide clinical and customer support 24 hours a day, seven days a week. Medela’s global R&D team is actively developing innovations in the wound care field.
“Customer focus is a core capability to the Medela organization. We’re also determined to develop innovative technology which continuously provides improved solutions for wound care. We believe these two ingredients will help us achieve our goal of significant market share in the near future,” says Roman Kupper, CEO, Medela Healthcare. “Our launch in the U.S. market is phase one. Further phases involve expanding into other international markets.”
About Medela:
Medela, a privately-held company, operates in the field of Medical Technology and Breastfeeding for use by patients and healthcare professionals across a wide range of therapies and care settings. Medela focuses on providing research based innovations for its customers. Medela, headquartered in Switzerland, serves customers through its 12 subsidiaries and a worldwide network of distribution partners in more than 90 countries. For more information, visit http://www.medelasuction.com
